Lexicon Pharmaceuticals, Inc.
) announced encouraging results from a phase II study on its
diabetes candidate, LX4211. The candidate, designed to lower
blood glucose levels through two insulin-independent mechanisms,
is being developed for the treatment of type 1 diabetes.
Results from the study revealed that LX4211 was successful in
reducing the total daily mealtime bolus insulin dose by a higher
percentage compared to placebo. This was the primary objective of
the study. Results further revealed that LX4211 significantly
improved glycemic control compared to that of placebo. Moreover,
the candidate was well tolerated during the study.
Meanwhile, Lexicon stated in its conference call that it has
submitted a request to the FDA regarding an end-of-phase-II
meeting for LX4211. Lexicon intends to initiate a phase III study
on the candidate for the type 1 diabetes indication by year end.
The main objective of the phase III study will be hemoglobin A1c
We are encouraged by Lexicon's progress with LX4211. The
successful development of LX4211 is important for the company.
However, at this point, the diabetes market looks extremely
crowded with the presence of companies like
Apart from LX4211, Lexicon also has telotristat etiprate and
LX1033 in its pipeline. Telotristat etiprate is currently being
developed for the treatment of carcinoid syndrome in a phase III
study. Meanwhile, LX1033 is in a phase II study to reduce
serotonin production without impacting brain serotonin levels.
Lexicon currently carries a Zacks Rank #3 (Hold). Some
better-ranked stocks include
Regeneron Pharmaceuticals, Inc.
). Both stocks carry a Zacks Rank #1 (Strong Buy).
AMGEN INC (AMGN): Free Stock Analysis Report
LEXICON PHARMA (LXRX): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
REGENERON PHARM (REGN): Free Stock Analysis
To read this article on Zacks.com click here.